Zarxio Countdown: Amgen Prepares To 'Compete Effectively' As Biosimilar Launch Looms
This article was originally published in The Pink Sheet Daily
Executive Summary
Last-ditch injunction request fails, and now pricing, reimbursement and naming (yes, still naming) are key questions.